



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/523,618

04/25/2006

Bruno Covelli

28558-501 NATL

1368

30623

7590

10/17/2008

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C

ATTN: PATENT INTAKE CUSTOMER NO. 30623

ONE FINANCIAL CENTER

BOSTON, MA 02111

EXAMINER

STROUD, JONATHAN R

ART UNIT

PAPER NUMBER

3774

MAIL DATE

DELIVERY MODE

10/17/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/523,618	Applicant(s) COVELLI, BRUNO	
	Examiner JONATHAN R. STROUD	Art Unit 3774	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 08 November 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-15 and 17-28 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) 1-15 and 17-28 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Response to Arguments

1. Applicant's arguments filed on 07/25/2008, concerning the 35 U.S.C. 103 rejections over Hoerstrup DE 19919625, have been fully considered but they are not persuasive. Applicant's arguments are unpersuasive for at least the following reasons: A suture ring is a broadly known element of heart valves, as evidenced by a number of patents, for instance, US 5,758,151 to Arru, element 6, for example only. Suture rings are a common feature of the product; further, as defined by the MPEP, an exemplary rationale for supporting a conclusion of obviousness includes "Applying a known technique to a known device ready for improvement to yield predictable results, further, the use of known technique to improve similar devices., Still further, Obvious to try. In the instant case, one of ordinary skill in the art at the time of invention would have known to apply the methods of Hoerstrup DE 19919625 to create a shaped autologous heart valve including the well-known shape of a suture ring, for the purpose of suturing the device into the heart wall, a common practice in the art.

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a

Art Unit: 3709

whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made

4. Rejections were made based on machine translations performed by Derwent, Google Translator, Babelfish and a standard Langenscheidt German-English English-German dictionary.

5. Claims 1-15 and 18-28 are rejected under 35 U.S.C. 103(a) as being anticipated by Hoerstrup DE 19919625 as claimed. Text between “ ” is present claims language, text between [] is examiner’s reasoning for applying prior art. Translations are reproduced in italics for clarity.

Hoerstrup anticipates the device as disclosed and claimed and as follows:

“Providing a biodegradable support, colonizing the support with homologous fibroblasts and/or myofibroblasts cells to form a connective tissue matrix [abstract translation: *(i) colonizing a biodegradable carrier with homologous fibroblasts and/or myofibroblasts so as to give a connective tissue matrix*]; optionally colonizing the connective tissue matrix with endothelial cells [abstract translation: *(ii) colonizing the matrix with endothelial cells*]; and fixing of the matrix to a non-degradable or poorly degradable frame construction [the “carrier” as discussed above; furthermore, in the applicant’s disclosure he sites that both the “non-degradable or poorly degradable frame construction” and “biodegradable support” can be constructed of PHA. Since both can be made of the same material, the use of the terms “biodegradable” and “poorly degradable” becomes

Art Unit: 3709

non-limiting. Any part of the device can be considered either the frame or the carrier; the base of the device can be the frame, and the flaps the carrier, since they can be made of the same material.], before and/or after the fixing to the frame construction, the connective tissue matrix is introduced into a pulsatile flow chamber in which it can be exposed to increasing flow rates, and the flow rate is increased continuously or discontinuously [abstract translation: *iii) introducing the matrix into a pulsating flow chamber (e.g. in a bioreactor) where it is subjected to a (dis)continuous flow rate*].

Furthermore, the addition of a “support” structure to Hoerstrup’s design is obvious, since it can be made of the same material, and it has been held that the selection of a known material based on its suitability for its intended use supports a prima facie case for obviousness (Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327, 65 USPQ 297 (1945)], MPEP 2144.07) See Ionescu 4,441,216, Penny, III 4,816,029, and Rosen 4,345,340 for examples of stented heart valves.

Furthermore, the addition of a “suture ring” to Hoerstrup’s design is obvious, since suture rings are well-known elements of the base product of the process – the heart valve – that fill a well-known need. It would have been obvious to one of ordinary skill in the art to apply this known technique taught by Hoerstrup to the obvious design choice of a suture ring, which would yield predictable results.

The rearrangement of the steps in claim 2 does not change the process or product produced. It has been held that when the claimed and prior art products are identical in composition, a prima facie case of either anticipation or obviousness has been established. See *In re Best*, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA

Art Unit: 3709

1977). “When the PTO shows a sound basis for believing that the products of the applicant and the prior art are the same, the applicant has the burden of showing that they are not.” In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). See MPEP 2112.01 [R-3].

6. Further, Hoerstrup teaches the device as discussed above where it is firmly connected the biodegradable support is a biodegradable polymer matrix or an acellular biological matrix, a polyglycolic acid (PGA), polylactic acid (PLA), polyhydroxyalkanoate (PHA), poly-4-hydroxybutyrate (P4HB) or a mixture of two or more of these polymers [[col. 2 ll. 65-68, col. 3 ll. 1-10], [*“ ...above said biodegradable carrier includes PHA, PGA, PLA and/or P4HB and combinations thereof*] the support has a polymer density of 40 to 120 mg/cm³ [col. 3 ll. 10-15], the support is a porous polymer having a pore size of 80 to 240 micrometers [col. 3 ll. 25-30] the fibers of the support have a diameter of 6 to 20 micrometers [col. 3 ll. 20-25], the support is the connective tissue framework of an animal or human heart valve [col. 3 ll. 33-39], the step of colonization with fibroblasts or myofibroblasts is repeated 3 to 14 times [col. 4 ll. 29 - 48] approximately 10⁵ to 6 x 10⁸ fibroblasts or myofibroblasts are employed per square centimeter of support/matrix [col. 4 ll. 10-20] the step of colonization with endothelial cells is repeated 3 to 14 times [col. 4 ll. 40-48], approximately 10⁵ to 5 x 10⁸ endothelial cells are employed per square centimeter of support/matrix [col. 4 ll. 40-48], the cells are human cells, which are autologous [col. 4 ll. 49-52], the frame construction is made of a biocompatible material [the carrier is constructed of the same material as the matrix ... i.e. PGA, PLA or PHA as described above], flow rates of 5 ml/min to 8,000 ml/min are

Art Unit: 3709

established in the pulsatile flow chamber [col. 9 ll. 5-8: *range of 50-5,000 ml/min* anticipates the claimed range], the flow rate is increased over a period of 1 week to 12 weeks [col. 9 ll. 18-39, a 15-day increase falls within and anticipates the claimed range], the initial flow rate is 50 to 100 ml/min, the initial pulse frequency is 5 to 10 pulses/min, the flow rate is increased to 5,000 ml/min, the pulse frequency is increased to 180 pulses/min [col. 9 ll. 5-18], systemic pressures of 10 to 240 mm Hg are established in the pulsatile flow chamber [col. 9 ll. 40-44].

7. Claims 25-28 are anticipated by Hoestreup, since the heart valve claimed can be produced with the procedure as claimed above. See further col. 10 ll. 5-10 [collagen density of 43-55 %] and col. 10 ll. 9-15 [translation: *heart valve designed to withstand the flow conditions within the human heart*].

Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Hoerstrup in view of Rose 4,627,879. Hoerstrup teaches the invention as claimed and as discussed above, but fails to disclose the following claimed limitations taught by Rose: using fibrin adhesive to adhere the support structure to the seeded matrix [col. 1 ll. 14-49]. It would have been obvious to one of ordinary skill in the art at the time of invention to modify Hoerstrup in view of Rose, in order to achieve a biocompatible, biodegradable seal between the matrix and carrier that preserves the qualities of porous grafts and the achieves hemostasis, as taught by Rose [col. 1 ll. 14-49].

Conclusion

2. All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

10. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. See references cited.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jonathan R. Stroud whose telephone number is 571-

Art Unit: 3709

270-3070. The examiner can normally be reached on Monday through Friday, 7:30 a.m. to 5 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dave Isabella whose telephone number is 571-272-4749. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

//Jonathan R Stroud/

Examiner, Art Unit 3774

/Thomas J Sweet/

Primary Examiner, Art Unit 3774

Application/Control Number: 10/523,618
Art Unit: 3709

Page 9